** Drug developer Sagimet Biosciences' SGMT.O shares rise 8.4% to $5.05
** Oppenheimer starts coverage with "outperform" rating and PT at $30 — a 543.8% premium to Thursday's close of $4.66
** Brokerage sees "underappreciated opportunity" in co's lead experimental drug, denifanstat, being developed to treat metabolic dysfunction-associated steatohepatitis (MASH)
** MASH is a severe liver disease caused by fat buildup, leading to inflammation and damage
** The MASH market is dominated by Madrigal Pharmaceuticals' MDGL.O Rezdiffra
** "We see SGMT as ultimately benefiting from MDGL's build-out of the MASH market as diagnosis rates and reimbursement improve," brokerage says
** Oppenheimer expects risk-adjusted peak total revenues of ~$1.9 bln for denifanstat in 2040
** Including session's move, stock down 8.5% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。